Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.

Terumo is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare.

Advanced Cardiovascular Systems, Inc. develops and manufactures cardiovascular medical products. It operates as a subsidiary of Abbott Laboratories. Its medical devices help patients with heart diseases in returning to active and productive lives and physicians for improving patient management and clinical outcomes. Advanced Cardiovascular Systems, Inc. is based in Santa Clara, California. it is currently known as Abbott Cardiovascular Systems.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas.

Biosensors International Group Ltd. develops, manufactures, and markets medical devices for interventional cardiology and critical care procedures. It operates through the following segments: Interventional Cardiology, Critical Care, Cardiac Diagnostic, and Licensing Revenue. The company was founded in 1990 by Yoh Chie Lu and is headquartered in Singapore.

Chonnam National University Hospital is a university hospital in Gwangju, South Korea.

The 301 Hospital (Chinese: 三〇一医院) or People's Liberation Army General Hospital (Chinese: 中国人民解放军总医院), which constitutes simultaneously the PLA Postgraduate Medical School (Chinese: 中国人民解放军医学院), located in Beijing, China, is a military hospital directly subsidiary to Logistic Support Department of the Central Military Commission and the largest general hospital under the auspices of the People's Liberation Army. Its mission includes assuring the health of PLA and China's leaders.

Lepu Medical Technology (Beijing) Co. Ltd. engages in the research, development, production, and sale of medical equipment and accessories. Its products include medical equipment such as stent systems, interventional cardiology products, including rapamycin-eluting stents, percutaneous transluminal coronary angioplasty balloon dilatation catheters, guide wires and radial artery compression tourniquets; occlusion devices, including ductus arteriosus occlusion devices, ventricular septal defect occlusion devices and atrial septal defect occlusion devices, among others; anesthetic products, including blood pressure transducers, central venous catheters and infusion pumps; general medical care products, including blood sampling kits, needle-free connectors and accessories, as well as medical equipment and peripheral vascular interventional products. The company was founded on June 11, 1999 and is headquartered Beijing, China.

Shenzhen Salubris Biomedical Engineering Co., Ltd. engages in the research and development, manufacture, and wholesale of medical equipment. The company was founded on March 13, 2009 and is headquartered in Shenzhen, China.

Skynor Medical Technology (Shanghai) Co. Ltd. is a company headquartered in Shanghai, China. The firm manufactures and markets cardio vascular devices. It was founded in 2014 by Zhen Xin Zhao.

Seoul National University Hospital (서울대학교병원) is one of the oldest and biggest hospitals in South Korea. It is a general and teaching hospital of Seoul National University's College of Medicine. Except SNUH Healthcare System Gangnam Center, all branches have an emergency department (ED).

Xi'an Lianchuang Advanced Manufacturing Professional Incubator Co., Ltd., established on 2005-06-17, Business scope includes3DR&D and sales of printing equipment and materials;Production and sales of medical devices;mold making,Machining,mold resin,New product development and sales of processable plastics and adhesives;Equipment,electronics,Chemical Products(Does not contain flammable and explosive dangerous goods,Monitoring Precursor Chemicals),Development and sales of computer application software;Design and construction of laboratory engineering;industrial design,Technical Advisory Services;System job(member)worker training.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Beijing Kangrongyuan Medical Equipment Co., Ltd., established on 2013-06-26, Business scope includes wholesale of medical devicesIIIkind(The medical device business license is valid until2025year01moon14day);Sales of medical devices(Ikind),Equipment,Chemical Products(Free of Hazardous Chemicals),Instrumentation,computer,Software and Auxiliary Equipment,automobile parts,Wujinjiaodian(E-bike not included),stationery,sporting goods,hygiene products;Technical extension services;Undertake the exhibition;Conference Services;Family labor service;design,make,acting,Place an ad;Economic Information Consulting.(Market entities independently choose business projects in accordance with the law,Carry out business activities;and items that are legally subject to approval,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Specialized Vascular Technologies, Inc. develops technologies to improve the safety and efficacy of drug eluting stent. The company was incorporated in 2007 and is based in Fremont, California.

Suzhou Ai Ruide Medical Technology Co., Ltd., established on 2012-07-26, Business scope includes research and development of medical devices;Production:medical instruments;medical instruments,Technology development in the field of biomedicine,technology transfer,technical consulting,Technical Services;Enterprise Marketing Planning;market research;Business Consulting,Business Management Consulting Services;Self-operated and agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Xi'an Bono Electronic Technology Co., Ltd., established on 2009-02-03, Business scope includes research and development of medical devices,Maintenance and Technical Consulting Services;Research and development of electronic products,Sales;Software development and sales;Marketing Planning of Medical Devices(The above business scope does not include pre-licensing and exclusive control stipulated by the state,Prohibited items).

Wuxi Zhongke Guangyuan Biomaterials Co., Ltd., established on 2008-07-24, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of bio-based materials;Import and export;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.